Intarcia Therapeutics Gets $210M For Diabetes Treatments
Hayward-based Intarcia Therapeutics announced Thursday that it has raised $210M in a combination of equity and debt. The developer of diabetes treatment said it raised $160M in a preferred stock private placement, and $50M in private debt. Investors in the funding included New Enterprise Associates, New Leaf Venture Partners Venrock, The Baupost Group, Farallon Capital Management, and three additional un-named institutional investors. Intarcia is developing treatment for type 2 diabetes, and is about to launch a Phase 3 program.
posted on Thursday, November 15, 2012 (Link to more information)
Related companies:
Intarcia Therapeutics
Related stories:
> Intarcia Therapeutics Finds $50M
> NGM Biopharmaceuticals Gets $50M For Diabetes, Obesity Treatments
> Iconic Therapeutics Finds $20M
> Audentes Therapeutics Gets $42.5M For Rare Diseases
> Stanford Spinout SiteOne Therapeutics Gets Funding
silicontap.com Home